CXCL16 and prostate cancer: The CXCR6‐CXCL16 axis also promotes docetaxel resistance through phosphorylation of GSK‐3β, NF‐κB and ERK1/2 [60], as well as angiogenesis in prostate cancer via AKT/mTOR‐mediated regulation of VEGF and IL‐8 [61].